Literature DB >> 28931195

Hereditary hemorrhagic telangiectasia-laser treatment of epistaxis.

Gorazd Poje1, Marcel Marjanović Kavanagh.   

Abstract

Hereditary hemorrhagic telangiectasia (HHT) is a rare, autosomal dominant disorder characterized by recurrent epistaxis, telangiectasias, and multiorgan vascular dysplasia. Various modalities exist for the treatment of HHT-related chronic epistaxis, although no method is preferred over another. The aim of this study was to review the effectiveness of diode laser photocoagulation in the treatment of epistaxis in patients with HHT. The study included 17 patients (7 men, 10 women) treated with diode laser photocoagulation from year 2008 to 2012. All patients met the Curaçao criteria for a diagnosis of HHT. Patients were followed for 1 year. Treatment success was assessed using a custom questionnaire and total blood counts. After laser photocoagulation, the frequency and intensity of bleeds were reduced significantly and average hemoglobin concentrations improved at the 4-month assessment. After laser treatment, no patient required septodermoplasty; therefore, we suggest that every patient with HHT should be treated with laser photocoagulation. Diode laser treatment is a simple and effective procedure that should be considered when treating HHT.

Entities:  

Mesh:

Year:  2017        PMID: 28931195

Source DB:  PubMed          Journal:  Ear Nose Throat J        ISSN: 0145-5613            Impact factor:   1.697


  2 in total

Review 1.  Laser-Assisted Control of Epistaxis in Hereditary Hemorrhagic Telangiectasia: A Systematic Review.

Authors:  Arash Abiri; Khodayar Goshtasbi; Marlon Maducdoc; Ronald Sahyouni; Marilene B Wang; Edward C Kuan
Journal:  Lasers Surg Med       Date:  2019-08-22       Impact factor: 4.025

2.  Endoscopic surgical treatment of epistaxis in hereditary haemorrhagic telangiectasia: our experience.

Authors:  Fabio Pagella; Alessandro Pusateri; Eugenia Maiorano; Giuseppe Spinozzi; Sara Ugolini; Roberta Lizzio; Rosolino Mirabella; Carmine Tinelli; Carla Olivieri; Elina Matti
Journal:  Acta Otorhinolaryngol Ital       Date:  2021-02       Impact factor: 2.124

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.